Thiamidol in Melasma in Patients of Skin of Color: A Preliminary Report of Efficacy and Safety.

IF 2 Q3 DERMATOLOGY

Indian Dermatology Online Journal Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI:10.4103/idoj.idoj_1170_24

Rashmi Sarkar, Anjali Sahu, Vibhu Mendiratta, Sonali Langar

{"title":"Thiamidol in Melasma in Patients of Skin of Color: A Preliminary Report of Efficacy and Safety.","authors":"Rashmi Sarkar, Anjali Sahu, Vibhu Mendiratta, Sonali Langar","doi":"10.4103/idoj.idoj_1170_24","DOIUrl":null,"url":null,"abstract":"Background: Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders.Objective: This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma.Patients and methods: Ten Indian women with Fitzpatrick skin types III-V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores.Results: The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting.Limitations: A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol's efficacy in combination therapies and assess its long-term benefits.Conclusion: Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"16 5","pages":"760-764"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419698/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Dermatology Online Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/idoj.idoj_1170_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Melasma poses significant therapeutic challenges, especially in patients with skin of color, due to the increased risk of post-inflammatory hyperpigmentation. Thiamidol, a novel topical tyrosinase inhibitor, has demonstrated potential efficacy with a favorable safety profile in treating hyperpigmentation disorders.

Objective: This case series evaluates the efficacy and safety of Thiamidol in women of skin of color with melasma.

Patients and methods: Ten Indian women with Fitzpatrick skin types III-V and melasma applied 0.2% Thiamidol twice daily for 12 weeks. Outcomes were measured using the modified Melasma Area and Severity Index (mMASI) and patient satisfaction scores.

Results: The average reduction in mMASI was 34.4%, with patient satisfaction averaging 62%. Reported adverse effects were minimal and self-limiting.

Limitations: A small sample size and the lack of a control group limit generalizability of the results. Future research should explore thiamidol's efficacy in combination therapies and assess its long-term benefits.

Conclusion: Thiamidol is a promising and well-tolerated treatment for melasma in patients with skin of color.

Abstract Image

查看原文本刊更多论文

硫胺醇治疗有色皮肤患者黄褐斑：疗效和安全性的初步报告。

背景：由于炎症后色素沉着的风险增加，黄褐斑给治疗带来了重大挑战，特别是对有色皮肤患者。硫胺醇是一种新型的局部酪氨酸酶抑制剂，在治疗色素沉着症中具有良好的安全性和潜在的疗效。目的：评价硫胺醇治疗有色皮肤黄褐斑的疗效和安全性。患者和方法：10例Fitzpatrick皮肤III-V型及黄褐斑的印度女性应用0.2%硫氨醇，每日2次，连续12周。使用改良的黄褐斑面积和严重程度指数（mMASI）和患者满意度评分来衡量结果。结果：mMASI平均下降34.4%，患者满意度平均62%。报告的不良反应是最小的和自我限制的。局限性：小样本量和缺乏对照组限制了结果的普遍性。未来的研究应探索硫胺醇在联合治疗中的疗效，并评估其长期效益。结论：硫胺醇是一种治疗有色皮肤黄褐斑的好方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊